The New York Entrepreneur

Dow Jones Newswires: Japan’s Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion

Read Time:9 Second

The Japanese company said it would pay $40.00 per share of Iveric, which booked net loss of $185.2 million and had $534.7 million in net assets in 2022.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Dow Jones Newswires: NEC Corp. shares rise in Tokyo after fiscal-year operating profit surges 29%
Next post Dow Jones Newswires: NEC Corp. shares rise in Tokyo after fiscal-year operating profit surges 29%